Effects of mescaline and some of its analogs on cholinergic neuromuscular transmission
Emmanuel Ghansah, Prapaporn Kopsombut, M A Maleque, A. Brossi
Neuropharmacology February 1, 1993 DOI: 10.1016/0028-3908(93)90097-m (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Laboratory study Peer reviewed |
|---|---|
| Population | Frog sciatic-sartorius preparations and rat cortical tissue |
| Interventions | Mescaline Anhalinine Methylenemescaline trimer |
| Dose | 10-100 microM |
| Topics | Mescaline |
| Keywords | Neuromuscular transmission Nicotinic agonist Cholinergic Acetylcholine receptor Pharmacology Neurotransmission Biophysics Endocrinology |
| Citations | 22 |
| Key points | Mescaline and its analogs inhibit cholinergic neuromuscular transmission by blocking acetylcholine release rather than by binding to nicotinic receptors, and they also affect potassium conductance. |
Abstract
Mescaline (3,4,5-trimethoxyphenylethylamine; MES) and its analogs, anhalinine (ANH) and methylenemescaline trimer (MMT) were investigated, using sciatic-sartorius preparations of the frog and cortical tissue from the rat. The effects of MES and its analogs were examined with respect to muscle twitch, resting membrane potential and nicotinic receptor binding. Mescaline and its analogs (10-100 microM) blocked both directly and neurally evoked twitches but their effects on neurally evoked twitches were greater than those on directly evoked twitches. Mescaline, ANH and MMT decreased amplitude of the miniature endplate and endplate potentials, decreased acetylcholine (ACh) quantal content, hyperpolarized the resting membrane potential and prolonged duration of the action potential. They did not significantly displace the binding of [125I]-alpha-bungarotoxin (alpha-BTX) to nicotinic receptors, at concentrations which blocked neuromuscular transmission. These results suggest that MES and its analogs inhibit cholinergic neuromuscular transmission by blocking release of ACh; they also affect K+ conductance.
Comparable studies
Other experimental studies on mescaline, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Enzymatic Formation of Psychotomimetic Metabolites from Normally Occurring Compounds Rabbit lung | 1961 | Experimental study | |
| PSYCHOTOMIMETICS, CLINICAL AND THEORETICAL CONSIDERATIONS: HARMINE, WIN-2299 AND NALLINE Schizophrenic patients | 1957 | Experimental study | |
| Phencyclidine, Lysergic Acid Diethylamide, and Mescaline: Cerebral Artery Spasms and Hallucinogenic Activity Isolated basilar and middle cerebral arteries | 1981 | Experimental study | |
| Acquired and Crossed Tolerance to Mescaline, LSD-25, and BOL-148 | 1959 | Experimental study | |
| Effects of Hallucinogenic and Tranquilizing Drugs on Serotonin Evoked Uterine Contractions. Uterus of spayed rat | 1956 | Experimental study |
Citations in the library
Cited by 9
- Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions Current Molecular Pharmacology October 15, 2018
- Mescaline: The forgotten psychedelic Neuropharmacology October 14, 2022
- The Native American Church, Peyote, and Health: Expanding Consciousness for Healing Purposes Contemporary Justice Review December 1, 2007
- An Overview on the Hallucinogenic Peyote and Its Alkaloid Mescaline: The Importance of Context, Ceremony and Culture Molecules December 5, 2023
- Alkaloids of the Cactaceae — The Classics Natural Product Communications April 20, 2026
and 4 more in the library